Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ted collaboration with GSK. As part of Regulus' strategic alliance with GSK, Regulus received a $15 million upfront fee, which it began amortizing into revenue in the second quarter of 2008 and will continue to amortize over its six-year period of performance under the agreement.

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $1.8 million and $3.0 million for the three and six months ended June 30, 2008. With the recently announced strategic alliance with GSK, it is anticipated that Regulus' expenses will increase as Regulus continues to advance its research and development activities. The GSK alliance enhances Regulus' ability to expand operations and advance its programs. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.2 million and $2.2 million for the three and six months ended June 30, 2008. Regulus' non-cash compensation expense related to stock options was $681,000 and $1.1 million for the three and six months ended June 30, 2008. Because Regulus was formed in the third quarter of 2007, it did not have operating results in the first half of 2007.

Quarterly Highlights

"Since the completion of our Genzyme collaboration, we've made great progress with mipomersen by initiating the first of four studies scheduled to begin by year end and receiving a patent allowance that gives the Isis-Genzyme Apolipoprotein B franchise broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of our partnered drugs and satellite companies in the first half of the year, we continue to maximize the economic potential of our business model and our technology, while enabling the advancement of a broad portfolio of both partnered and internally developed drugs," concluded Ms. Parshall.

Cardiovascular Program

-- Completed licensing transaction for mipomersen

-- Finalized and announ
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... , Sept. 12, 2014 Research ... "Global Dry Film Photoresist Industry Report 2014" ... Dry Film Photoresist Industry Report 2014 is a professional ... global dry film photoresist industry . The ... definitions, classifications, applications and industry chain structure. The dry ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
Breaking Biology Technology:Global Dry Film Photoresist Industry Report 2014 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3
... Feb. 28, 2011 Idenix Pharmaceuticals, Inc. (Nasdaq: ... discovery and development of drugs for the treatment of ... the fourth quarter and year ended December 31, 2010. ... totaled $46.1 million. Business HighlightsIDX184 ...
... SAN DIEGO, Feb. 28, 2011 Verenium Corporation (Nasdaq: ... of high-performance specialty enzymes, today announced that Terminal 6, ... has successfully begun use of Verenium,s Purifine enzymatic degumming ... Argentina. Purifine enzymatic degumming is a novel process that ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that it ... Conference on Thursday, March 3rd at 10:25 AM Pacific ... Center, Seattle, Washington. WBBA Life Science Innovation Northwest ConferenceCTI ... PM CETRoom 607, Washington State Conference CenterMedia Contact:Dan Eramian ...
Cached Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 2World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 3World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 4
(Date:9/12/2014)... extraction of type I collagen fibrils, in vitro as ... circular cross sections stay distributed in a range going ... of them. Jean Charvolin and Jean-Francois Sadoc from the ... therefore that, once the growth of the fibrils has ... be limited by internal physical stresses generated during the ...
(Date:9/12/2014)... strange thing happened on the way to dealing ... trillions of dollars, worth of previously unreachable oil ... environmental costs and benefits from "fracking," ... and chemicals deep into underground rock formations, are ... academic studies and government databases. The survey covers ...
(Date:9/12/2014)... Washington , September 12, 2014 ... source covering leading sectors including biometrics and mobile tech, issues ... launch of Apple Pay, its new payment service. ... founder of the Secure Identity and Biometrics Association (SIBA) and ... NXTD ) a company that is introducing its own ...
Breaking Biology News(10 mins):Conjecture on the lateral growth of Type I collagen fibrils 2Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5
... the largest scientific conference devoted primarily to osteoporosis, will ... session focused on four key topics in nutrition and ... the MRC Epidemiology Resource Centre at the University of ... the University of Oxford, will speak on the developmental ...
... improve forecasts of dust storms in the American Southwest ... announced the finding as a five-year NASA-funded project nears ... of the University of New Mexico in Albuquerque, and ... scientists evaluated the influence of space-based observations on predictions ...
... year, some 29,000 adults and 2,000 children are diagnosed with ... abnormal production of white blood cells in the bone marrow. ... also destroys normal cells. But what if a way could ... A team of Syracuse University researchers believes it may have ...
Cached Biology News:Nutrition and bone health session to open the IOF World Congress on Osteoporosis in Bangkok 2NASA-enhanced dust storm predictions to aid health community 2NASA-enhanced dust storm predictions to aid health community 3Syracuse University researchers discover new way to attack some forms of leukemia 2Syracuse University researchers discover new way to attack some forms of leukemia 3
... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: